Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387246 | 0.79 | CYP3A4 (0.58) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL10025891 | 0.79 | CYP3A4 (0.58) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL5233561 | 0.78 | CYP3A4 (0.57) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL14337774 | 0.78 | CYP3A4 (0.57) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL4043528 | 0.78 | ALDH1A1 (0.57) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL8144226 | 0.78 | CYP3A4 (0.57) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL12781853 | 0.75 | CYP3A4 (0.54) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL12118415 | 0.75 | CYP3A4 (0.54) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL12000232 | 0.75 | CYP3A4 (0.77) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE | |
| SCHEMBL15240428 | 0.74 | ACHE (0.58) | CYP3A4ALDH1A1SMN1; SMN2POLBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| EP-3191484-B1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| CN-114507175-A | Novel inhibitors of hypnotic proteins alpha and beta | 维沃里翁治疗股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-109195947-B | Novel inhibitors of hypnotic proteins alpha and beta | 维沃里翁治疗股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3445744-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210198189-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-07-01 | — | — | US | disclosed |
| US-10975019-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS AG (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS N.V (DE) | 2019-05-02 | — | — | US | disclosed |
| US-10138242-B2 | Pyrazolopyridine derivatives and their use in therapy | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-20180186789-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| US-9840504-B2 | Pyrazolopyridine derivatives and their use in therapy | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGZENTRUM FUER GESUNDHEIT UN (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20170247375-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-08-31 | — | — | US | disclosed |
| EP-3191484-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038045-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-03-17 | — | — | WO | disclosed |
| EP-2993174-A1 | Pyrazolopyridine derivatives and their use in therapy | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247375-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | TPP1, PRDX5, TPMT | CYP3A4 625/4885ALDH1A1 1527/4885SMN1; SMN2 2964/4885 |
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | MEP1A, MEP1B, CAPRIN1 | CYP3A4 4062/4885ALDH1A1 3469/4885SMN1; SMN2 3617/4885 |
| US-20180186789-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | TPP1, PRDX5, TPMT | CYP3A4 625/4885ALDH1A1 1527/4885SMN1; SMN2 2964/4885 |
| US-20210198189-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | MEP1A, MEP1B, CAPRIN1 | CYP3A4 4062/4885ALDH1A1 3469/4885SMN1; SMN2 3617/4885 |
| US-10138242-B2 | Pyrazolopyridine derivatives and their use in therapy | TPP1, PRDX5, TPMT | CYP3A4 625/4885ALDH1A1 1527/4885SMN1; SMN2 2964/4885 |
| US-10975019-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | CYP3A4 4044/4885ALDH1A1 3070/4885SMN1; SMN2 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.